Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Mallinckrodt
Moodys
Express Scripts
Dow

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

KINEVAC Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Kinevac patents expire, and when can generic versions of Kinevac launch?

Kinevac is a drug marketed by Bracco and is included in one NDA. There is one patent protecting this drug.

This drug has ten patent family members in eight countries.

The generic ingredient in KINEVAC is sincalide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sincalide profile page.

Drug patent expirations by year for KINEVAC
Drug Prices for KINEVAC

See drug prices for KINEVAC

Generic Entry Opportunity Date for KINEVAC
Generic Entry Date for KINEVAC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INJECTION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for KINEVAC

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Penn State UniversityN/A
Johns Hopkins UniversityN/A
Temple UniversityN/A

See all KINEVAC clinical trials

Recent Litigation for KINEVAC

Identify potential future generic entrants

District Court Litigation
Case NameDate
BRACCO DIAGNOSTICS INC. v. MAIA PHARMACEUTICALS, INC.2017-12-15

See all KINEVAC litigation

PTAB Litigation
PetitionerDate
Maia Pharmaceuticals, Inc.2018-11-19

See all KINEVAC litigation

Pharmacology for KINEVAC
Synonyms for KINEVAC
(Tyr[SO3H]27)Cholecystokinin fragment 26-33 Amide
[125I]CCK-8
1-De(5-oxo-L-proline)-2-de-L-glutamine-5-L-methioninecaerulein
126S323
25126-32-3
25345-10-2
89911-55-7
9038-72-6
91921-74-3
A817659
AC1L1OGF
AKOS015896031
AKOS016340423
Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2
Asp-Tyr[SO3 H]-Met-Gly-Trp-Met -Asp-Phe-NH2
Asp-Tyr[SO3 H]-Met-Gly-Trp-Met-Asp-Phe-NH2
Asp26-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-PheNH2
BDBM21147
C49H62N10O16S3
Caerulein, 1-de(5-oxo-L-proline)-2-de-L-glutamine-5-L-methionine-
CAS-25126-32-3
CCK 26-33, sulfated
CCK C-terminal octapeptide
CCK-8
CCK-8 (sulphated)
CCK-8, sulfated
CCK-8(SO3)
CHEBI:135946
CHEMBL1121
cholecystokinin 8
cholecystokinin C-terminal octapeptide
cholecystokinin fragment 26-33 amide (sulphated)
Cholecystokinin octapeptide
Cholecystokinin Octapeptide, sulfated
Cholecystokinin-pancreozymin
CS-042
CS-5963
D05845
DB09142
DSSTox_CID_28543
DSSTox_GSID_48617
DSSTox_RID_82815
DTXSID7048617
EINECS 246-639-0
FT-0630515
GTPL864
H-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2
HS-2026
Human CCK-8
HY-P0093
I06-1840
IZTQOLKUZKXIRV-YRVFCXMDSA-N
Kinevac (TN)
L-alpha-Aspartyl-O-sulfo-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-alpha-aspartyl-L-phenylalaninamide
L-Aspartyl-L-tyrosyl-L-methionylglycyl-L-tryptophyl-L-methionyl-L-aspartylphenyl-L-alaninamide hydrogen sulfate (ester)
LS-53094
M03GIQ7Z6P
MFCD00079849
MolPort-006-124-517
NCGC00167273-01
NCGC00183278-01
NCGC00183363-01
O411
Pancreozymin
Pancreozymin C-terminal octapeptide
SC-47569
SCHEMBL122365
SCHEMBL1425223
Sincalida
Sincalida [INN-Spanish]
Sincalide
Sincalide (Kinevac)
Sincalide (USP/INN)
Sincalide [USAN:BAN:INN]
Sincalide [USAN:USP:INN:BAN]
Sincalidum
Sincalidum [INN-Latin]
SQ 19844
SQ-19844
Syncalide
Tox21_112955
Tox21_113481
UNII-M03GIQ7Z6P

US Patents and Regulatory Information for KINEVAC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco KINEVAC sincalide INJECTABLE;INJECTION 017697-001 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
McKinsey
Express Scripts
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.